Olema Pharmaceuticals (OLMA) grants major stock option awards to executive

Rhea-AI Filing Summary

Olema Pharmaceuticals granted new equity awards to a senior executive. Chief Discovery & Non-Clinical Development Officer Myles David C. received stock options for 250,000 shares at an exercise price of $25.65 per share, expiring on February 1, 2036.

For this time-based option, 25% of the shares vest on February 2, 2027, with the remainder vesting in equal monthly installments over the following three years, contingent on continued service. He also received 106,250 performance-based stock options at the same exercise price, eligible to vest in two performance periods running from February 2, 2026 through December 31, 2029 and December 31, 2030, based on the company’s stock trading above specified price thresholds and continued service at the certification dates.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Myles David C.

Role CH. DISCOV. & NON-CLIN DEV OFF

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	250,000	$0.00	--
Grant/Award	Performance Stock Options (Right to Buy)	106,250	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 250,000 shares (Direct); Performance Stock Options (Right to Buy) — 106,250 shares (Direct)

Footnotes (1)

1. 25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Myles David C.

(Last) (First) (Middle)

C/O OLEMA PHARMACEUTICALS, INC.

780 BRANNAN ST

(Street)

SAN FRANCISCO CA 94103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Olema Pharmaceuticals, Inc. [ OLMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CH. DISCOV. & NON-CLIN DEV OFF

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$25.65	02/02/2026		A		250,000		(1)	02/01/2036	Common Stock	250,000	$0	250,000	D
Performance Stock Options (Right to Buy)	$25.65	02/02/2026		A		106,250		(2)	02/01/2036	Common Stock	106,250	$0	106,250	D

Explanation of Responses:

1. 25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

2. The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date.

	/s/ Shawnte Mitchell, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options were granted to Olema (OLMA) executive Myles David C.?

Olema granted Myles David C. options on 250,000 shares of common stock at a $25.65 exercise price, expiring February 1, 2036. These are time-based options that vest gradually over four years, encouraging long-term alignment with company performance and retention.

How do the time-based stock options for Olema (OLMA) executive vest?

For the 250,000 time-based options, 25% of the shares vest on February 2, 2027. The remaining 75% then vest in equal monthly installments over the following 36 months, subject to the executive’s continuous service with Olema through each monthly vesting date.

What performance stock options did Olema (OLMA) grant and how many shares are included?

Olema granted 106,250 performance-based stock options to Myles David C. at a $25.65 exercise price. Each option relates to one share of common stock, and vesting depends on meeting stock price thresholds during specified performance periods and the executive’s continued service.

Over what periods can the Olema (OLMA) performance stock options vest?

The performance-based options can vest during two distinct performance periods, both starting February 2, 2026. One period ends December 31, 2029, and the other ends December 31, 2030, tying vesting to stock price performance measured over each period.

What conditions determine vesting of Olema (OLMA) performance stock options?

Vesting depends on Olema’s stock trading at pre-determined price thresholds, measured by the average closing price over a consecutive 30-day trading period. Once a threshold is met and certified by the Compensation Committee, the related portion vests if the executive remains in service on that certification date.

Does the Olema (OLMA) executive pay anything for these option grants?

The options are granted at no cost, but exercising them requires paying the $25.65 exercise price per share. The Form 4 shows a transaction price of $0 for the grant itself, which is typical for equity awards issued as part of executive compensation packages.